

**Comparative Study Between  
the Efficacy and Tolerability  
of Isradipine and Nifedipine  
in the Treatment of  
Mild to Moderate Hypertension**

***Thesis***

**Submitted In Partial Fulfillment of  
The Master Degree In Cardiology**

***By***

**Dr. Sultan Kassem Saeed**

***Supervised By***

**Prof. Dr. Mahmoud Al-Sherbini**

**Professor of Cardiology**

**Faculty of Medicine**

**Ain Shams University**

**Prof. Dr. Ahmed Nassar**

**Assis. Prof. of Cardiology**

**Faculty of Medicine**

**Ain Shams University**


**Dr. Samir Wafa**

**Lecturer of Cardiology**

**Faculty of Medicine**

**Ain Shams University**

**1991**




40453

616-132

S.K.

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ  
قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا  
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ  
صَدَقَ اللَّهُ الْعَظِيمُ  
سورة البقرة : آية ٢٢



## Acknowledgment

I would like to express my deepest gratitude and appreciation to Prof. Dr. **MAHMOUD EL-SHIRBINI**, Professor of Cardiology, Ain Shams University for his valuable guidance, kind help, constant advice and supervision of this thesis.

I would like to express my sincere thanks to Prof. Dr. **AHMED NASSAR**, Assistant Professor of Cardiology, Ain Shams University for his helpful advice, great cooperation and helpful suggestion and comments.

I also wish to express my fully thanks to DR. **Samir Wafa**, Lecturer of Cardiology, Ain Shams University for his persistent encouragement and cooperation were responsible for the production of this work.

# Contents

|                                                                                    | <u>Page</u> |
|------------------------------------------------------------------------------------|-------------|
| <b>Introduction</b>                                                                | <b>1</b>    |
| <b>Aim of the work</b>                                                             | <b>4</b>    |
| <b>Review of literature</b>                                                        | <b>5</b>    |
| * Pathophysiology of hypertension.                                                 | 5           |
| * Classification of blood pressure.                                                | 14          |
| * Role of calcium in initiating smooth muscle contractile activity.                | 15          |
| * Role of renin in essential hypertension.                                         | 23          |
| <b>Effects of calcium antagonists on systemic.</b>                                 |             |
| <b>Hemodynamics in hypertension.</b>                                               | <b>25</b>   |
| <b>Isradipine.</b>                                                                 | <b>37</b>   |
| * Pharmacology of isradipine.                                                      | 37          |
| * General properties and cardiac action.                                           | 38          |
| * Effects of isradipine metabolites detected in human circulation.                 | 41          |
| * Analysis of peripheral vascular action of the new calcium antagonist isradipine. | 41          |
| * Vasodilator effects in sodium depleted and supplemented animal.                  | 43          |
| * Antivasconstrictor effects.                                                      | 44          |
| * Modification of the hemodynamic effects by pendolol and spirapril.               | 45          |

|                                                 |     |
|-------------------------------------------------|-----|
| * Pharmacokinetics of isradipine.               | 48  |
| * Cardiovascular pharmacodynamic of isradipine. | 49  |
| * Adverse effects of isradipine.                | 50  |
| <b>Subjects and Methods.</b>                    | 51  |
| <b>Results and Statistical Analysis.</b>        | 58  |
| <b>Discussion.</b>                              | 85  |
| <b>Conclusion.</b>                              | 95  |
| <b>Recommendation.</b>                          | 97  |
| <b>Criticism and limitation of our study.</b>   | 98  |
| <b>Summary.</b>                                 | 99  |
| <b>References.</b>                              | 103 |
| <b>Arabic summary.</b>                          |     |

# List of Figures

| <b><u>Figure</u></b> |                                                 | <b><u>Page</u></b> |
|----------------------|-------------------------------------------------|--------------------|
| 1 -                  | Pharmacology of isradipine and its metabolites. | 37                 |
| 2 -                  | Normal doppler transmitral flow.                | 54                 |
| 3 -                  | Extent of diastolic blood pressure reduction.   | 60                 |
| 4 -                  | Efficacy evaluation comparison.                 | 62                 |
| 5 -                  | Side effects comparison.                        | 64                 |
| 6 -                  | Serum cholesterol results.                      | 68                 |
| 7 -                  | Serum triglycerides results.                    | 70                 |
| 8 -                  | Serum total lipids results.                     | 72                 |
| 9 -                  | Serum uric acid results.                        | 75                 |
| 10 -                 | Serum creatinine results.                       | 77                 |
| 11 -                 | heart rate evaluation.                          | 79                 |
| 12 -                 | Tolerability comparison.                        | 84                 |
| 13 -                 | Pre and post treatment ECG changes.             | 80                 |
| 14 -                 | Pre and post medication E/A ratio               | 82                 |
| 15 -                 | Pre and post medication ejection fraction       | 83                 |

## List of Tables

| <b><u>Table</u></b>                                    | <b><u>Page</u></b> |
|--------------------------------------------------------|--------------------|
| 1 - Classification of blood pressure.                  | 14                 |
| 2 - Extent of mean diastolic blood pressure reduction. | 59                 |
| 3 - Efficacy evaluation grades percentage.             | 62                 |
| 4 - Side effects comparison.                           | 64                 |
| 5 - Serum cholesterol results.                         | 67                 |
| 6 - Serum triglycerides results.                       | 69                 |
| 7 - Serum total lipids results.                        | 71                 |
| 8 - Serum uric acid results.                           | 74                 |
| 9 - Serum creatinine results.                          | 76                 |
| 10 - Heart rate evaluation.                            | 78                 |
| 11 - Tolerability grades percentage.                   | 84                 |



## List of Abbreviations

|                  |   |                                     |
|------------------|---|-------------------------------------|
| ATP              | = | Adenosine triphosphate.             |
| ATP ase          | = | Adenosine triphosphatase.           |
| BP               | = | Blood pressure.                     |
| CAMP             | = | Cyclic adenosine monophosphate.     |
| CA <sup>++</sup> | = | Calcium.                            |
| DL               | = | Deciliter.                          |
| ECG              | = | Electrocardiogram.                  |
| HDL              | = | High density lipoprotein.           |
| LDL              | = | Low density lipoprotein.            |
| MG               | = | Magnesium.                          |
| MG ATPase        | = | Magnesium adenosine triphosphatase. |
| mg               | = | Melli gram.                         |
| μG               | = | Micro gram.                         |
| PN 200 - 110     | = | Isradipine.                         |
| SAN              | = | Sine atrial node.                   |

INTRODUCTION

# Introduction and aim of the work

## Introduction :

Calcium ions play a critical role in many vital biological processes in all cells.

Within the cardio-vascular system, calcium is importantly involved in the activation of cardiac cells the genesis of the action potential, the coupling of electrical activation to myocardial activation and the constriction of vascular smooth muscle.

Calcium antagonists which block the entry of calcium into cardiac and vascular smooth muscle cell, represent one of the most important development in cardiovascular therapeutics in the latter half of this century<sup>1</sup>.

In essentially hypertension, indices of calcium and magnesium metabolism are shifted in both directions away from average normotensive values and are related to concurrent shift in the rennin system<sup>2</sup> thus patients with low rennin essential hypertension had the lowest level of ionized calcium . These levels were significantly lower than those in patients with medium or high rennin hypertension or in normotensive controls.

Plasma rennin activity demonstrated a significant positive correlation with serum levels of ionized calcium and varied inversely with serum magnesium levels.

The action of the calcium antagonists appears to depend on the level of rennin activity and of serum ionized calcium these agents such as isradipine and nitrendipine are most effective in lowering blood pressure in patents with the lowest level of rennin activity and ionized calcium and are relatively in effective in patients with high rennin<sup>3</sup> essential hypertension.

The newer calcium entry blockers appear to have more pronounced selectivities than verapamit nifedipine and deltiazen.

Agents such as nisoldipine, darodipine, isradipine and several others are almost devoid of cardiodepressant effects at therapeutic doses, although other actions at the level of the heart are also apparent.

Isradipine is a new calcium antagonist with a very high affinity for L-type calcium channels. As a result isradipine shows a marked selectivity for a few specific tissues such as the sinus node but not atrio-ventricular conduction and

especially the coronary, cerebral and skeletal muscle vascular beds<sup>4</sup>.

## **Aim of the work**

The aim of this study is to compare between the efficacy and tolerability of isradipine and nifedipine in treatment of mild to moderate essential hypertension.

# REVIEW OF LITERATURE